Transforming ovarian cancer care by targeting minimal residual disease

Amir A. Jazaeri, Rachel Grisham, Anne Knisely, Stefani Spranger, Dmitriy Zamarin, R. Tyler Hillman, Barrett C. Lawson, Kathleen H. Burns, Sanghoon Lee, Shannon N. Westin, Enrico Moiso, Marc J. Williams, Neelkanth M. Bardhan, Thomas Pisanic, Ursula Matulonis, Britta Weigelt, Ie Ming Shih, Panagiotis A. Konstantinopoulos, Stephanie Gaillard, Linghua WangCarol Aghajanian, Alan D. D'Andrea, Paula Hammond, Sohrab Shah, Kai W. Wucherpfennig, Karen H. Lu

Research output: Contribution to journalComment/debatepeer-review

Abstract

Frontline treatment and resultant cure rates in patients with advanced ovarian cancer have changed little over the past several decades. Here, we outline a multidisciplinary approach aimed at gaining novel therapeutic insights by focusing on the poorly understood minimal residual disease phase of ovarian cancer that leads to eventual incurable recurrences.

Original languageEnglish (US)
Pages (from-to)755-760
Number of pages6
JournalMed
Volume4
Issue number11
DOIs
StatePublished - Nov 10 2023

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Transforming ovarian cancer care by targeting minimal residual disease'. Together they form a unique fingerprint.

Cite this